Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome

Gynecological Endocrinology

Volumn 27, Issue 7, 2011, Pages 491-495

  Cakal, Erman ^a,e   Ustun, Yusuf ^b   Engin Ustun, Yaprak ^c   Ozkaya, Mesut ^d   Kilinç, Metin ^d  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Medicana International Hospital   (Turkey)

^c Zekai Tahir Burak Mother Health Training and Research Hospital   (Turkey)

^d KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^e Kirkkonaklar Mah   (Turkey)

Author keywords

PCOS; vaspin

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VASPIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; SERPINS;

EID: 79958026437     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.501874     Document Type: Article

References (27)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082. (Pubitemid 28500937)
2. Balen A, Rajkowa M. Polycystic ovary syndrome - a systemic disorder? Best Pract Res Clin Obstet Gynaecol 2003;17: 263-274. (Pubitemid 36647985)
3. Engin-Ustun Y, Ustun Y, Meydanli MM, Kafkasli A, Yetkin G. Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome? Gynecol Endocrinol 2006;22:324-328. (Pubitemid 43941409)
4. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JMC, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2453-2455. (Pubitemid 32545690)
5. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-10615. (Pubitemid 41061602)
6. Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008;93:247-251.
7. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-377.
8. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-1507.
9. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol 1999;51:779-786. (Pubitemid 30050829)
10. Norman RJ, Hague WM, Masters SC, Wang XJ. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod 1995;10:2258-2261.
11. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, Lobo RA. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-909. (Pubitemid 27271742)
12. Battaglia C, Mancini F, Cianciosi A, Busacchi P, Facchinetti F, Marchesini GR, Marzocchi R, de Aloysio D. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol 2008;111:385-395. (Pubitemid 351653430)
13. Lakhani K, Seifalian AM, Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 2002;106:81-85. (Pubitemid 34747446)
14. The Rotterdam ESHRE/ASRM-Sponsored PCOS Workshop Group. Revised 2003 consensus on diagnostic and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
15. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: 1440-1447.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
17. Tilg H, Moschen AR. Adipocytokines. Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783. (Pubitemid 44453463)
18. Ozkaya M, Cakal E, Ustun Y, Engin-Ustun Y. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril 2010;93:880-884.
19. Cakal E, Ozkaya M, Engin-Ustun Y, Ustun Y. Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. J Endocrinol Invest 2010 May 28 (Epub ahead of print).
20. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine, and ultrasound features in 556 patients. Clin Endocrinol 1989;30:459-470. (Pubitemid 19110020)
21. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800. (Pubitemid 28009567)
22. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169. (Pubitemid 29036695)
23. Cenk Sayin N, Gucer F, Balkanli-Kaplan P, Ali Yuce M, Yardim T. Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome. Gynecol Endocrinol 2003;17: 387-396. (Pubitemid 37338869)
24. Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004;89: 4343-4350. (Pubitemid 39244436)
25. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97: 3A-11A. (Pubitemid 43139714)
26. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid artery hemodynamics in women with polycystic ovaries. Clin Sci 2000;98:661-665. (Pubitemid 30386428)
27. Birdsall MA, Farquar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-35. (Pubitemid 27021216)